Immunodiagnostic Systems Hldgs PLC Director/PDMR Shareholding (0340Z)
18 Mai 2021 - 3:33PM
UK Regulatory
TIDMIDH
RNS Number : 0340Z
Immunodiagnostic Systems Hldgs PLC
18 May 2021
Immunodiagnostic Systems Holdings PLC
Director/PDMR Dealing
18 May 2021
Immunodiagnostic Systems Holdings PLC ("IDS") a specialist
producer of manual and automated diagnostic testing kits and
instruments for the clinical and research markets, announces that
it has granted the following options to persons discharging
managerial responsibilities to acquire ordinary shares of 2p in the
capital of the Company under the Company's Co-Investment Executive
Option Scheme ("Scheme").
Employee Position Grant Date Number Exercise
of Options Price
Jaap Stuut Chief Executive Officer 17-May-21 7,500 1.95
--------------------------- ------------ ------------ ---------
Paul Martin Chief Financial Officer 17-May-21 6,300 2.75
-------------------- --------------------------- ------------ ------------ ---------
17-May-21 6,000 1.95
------------------------------------------------------------- ------------ ---------
Nicola Trewin Group HR Director 17-May-21 3,000 1.95
--------------------------- ------------ ------------ ---------
Soenke Weissenborn Group Operations Director 17-May-21 6,000 2.49
-------------------- --------------------------- ------------ ------------ ---------
17-May-21 6,000 2.27
------------------------------------------------------------- ------------ ---------
Under this Scheme, participants who purchase ordinary shares in
the Company ("Co-Investment Shares") are entitled to three share
options for each Co-Investment Share they purchase. The exercise
price for the options is set at the price the participant paid for
each Co-Investment Share.
The options are subject to the satisfaction of performance
conditions and vest after a period of 3 years for the date of
purchase of the Co-Investment Share. The options are exercisable
over the period of 10 years from the date of grant.
In accordance with the operation of the Scheme in previous
years, option awards were due to be granted on 31 March 2021
related to Co-Investment Shares purchased or rolled over in the
financial year ended 31 March 2021, however this was not possible
owing to the Company being in a close period.
All options granted at this time will be exercisable in full
shortly prior to the scheme of arrangement to be implemented to
effect the recommended cash offer for IDS by PerkinElmer (UK)
Holdings Ltd (as referred to in the announcement made yesterday)
becoming effective.
The below notifications, made in accordance with Article 19 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of
domestic law by virtue of the European Union (Withdrawal) Act 2018,
gives further detail of the number of options awarded.
For further information:
Immunodiagnostic Systems Holdings Tel : +44 (0)191
plc 519 0660
Paul Martin, Group Finance Director
Peel Hunt LLP Tel : +44 (0)207
418 8900
James Steel
Victoria Erskine
Notification and public disclosure of transactions by persons
discharging
managerial responsibilities and persons closely associated with
them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. Jaap Stuut
2. Paul Martin
3. Nicola Trewin
4. Soenke Weissenborn
------------------------------ --------------------------------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------------------------------
a. Position/status 1. Chief Executive Officer
2. Chief Financial Officer
3. Group HR Director
4. Group Operations Director
------------------------------ --------------------------------------------------------------------
b. Initial notification Initial
/Amendment
------------------------------ --------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------------
a. Name Immunodiagnostic Systems Holdings plc
------------------------------ --------------------------------------------------------------------
b. LEI 213800HZMYTD4NGF4L78
------------------------------ --------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------
a. Description Options over ordinary shares of 2p each in Immunodiagnostic
of the Systems Holdings plc
Financial instrument,
Ordinary shares
type
of instrument
GB00B01YZ052
Identification
code
------------------------------ --------------------------------------------------------------------
b. Nature of the Grant of Options
transaction
------------------------------ --------------------------------------------------------------------
c. Price(s) and Employee Grant Date Number Exercise
volume(s) of Options Price
Jaap Stuut 17-May-21 7,500 1.95
------------ ------------ ---------
Paul Martin 17-May-21 6,300 2.75
-------------------- ------------ ------------ ---------
17-May-21 6,000 1.95
--------------------------------- ------------ ---------
Nicola Trewin 17-May-21 3,000 1.95
------------ ------------ ---------
Soenke Weissenborn 17-May-21 6,000 2.49
-------------------- ------------ ------------ ---------
17-May-21 6,000 2.27
--------------------------------- ------------ ---------
------------------------------ --------------------------------------------------------------------
d. Aggregated Employee Grant Date Number of Weighted Average
information Options Exercise Price
* Aggregated volume Paul Martin 17-May-21 12,300 2.360
------------ ---------- -----------------
Soenke Weissenborn 17-May-21 12,000 2.380
* Price ------------ ---------- -----------------
------------------------------ --------------------------------------------------------------------
e. Date of the 17-May-21
transaction
------------------------------ --------------------------------------------------------------------
f. Place of the Outside trading venue - shares to be admitted
transaction to AIM market of London Stock Exchange plc on
exercise of options
------------------------------ --------------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBXGDUGXBDGBI
(END) Dow Jones Newswires
May 18, 2021 09:33 ET (13:33 GMT)
Immunodiagnostic Systems (LSE:IDH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Immunodiagnostic Systems (LSE:IDH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
